Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma

Date

21 Oct 2023

Session

Poster session 07

Topics

Cancer Research

Tumour Site

Thoracic Malignancies

Presenters

Chi Cho

Citation

Annals of Oncology (2023) 34 (suppl_2): S1135-S1144. 10.1016/S0923-7534(23)01269-3

Authors

C.C. Cho1, Y. Chen2, W. Cheuk3, G.J. Liao3, E. Cheung2

Author affiliations

  • 1 Clinical Oncology Department, Queen Elizabeth Hospital, NA - Kowloon/HK
  • 2 Faculty Of Health Sciences, University of Macau, Taipa/MO
  • 3 Department Of Pathology, Queen Elizabeth Hospital, Kowloon/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2208P

Background

Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.

Methods

Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).

Results

Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.

Conclusions

Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.